Key result
Human stem cell-derived cardiomyocyte platform successfully discriminates cardiotoxic mechanisms of doxorubicin, aclarubicin, and amrubicin.
Why the study?
Cardiotoxicity is a major cause of drug withdrawal due to poor predictability of animal models, and it remains unclear which cancer patients will develop treatment-limiting heart failure.
Can a human pluripotent stem cell (hPSC)-derived cardiomyocyte platform predict molecular and functional cardiotoxicity of different anthracyclines?
Population
Human pluripotent stem cell (hPSC)-derived cardiomyocytes
Comparison
Doxorubicin vs Aclarubicin vs Amrubicin
Design
In vitro safety screening platform study
Follow-up
two or three weeks
Authors
Loading...
May enable individualized cardiotoxicity prediction; hypothesis-generating and requires prospective clinical validation.
Can a human pluripotent stem cell (hPSC)-derived cardiomyocyte platform predict molecular and functional cardiotoxicity of different anthracyclines?
An hPSC-derived cardiomyocyte platform can effectively model and differentiate the molecular and functional cardiotoxic mechanisms of various anthracyclines, offering a potential tool for individualized cardio-oncology screening.
Schwach et al. (2024) studied Cardiotoxicity. hPSC-derived cardiomyocyte screening platform was evaluated on Molecular and functional aspects of cardiotoxicity. A human pluripotent stem cell-derived cardiomyocyte platform successfully discriminated between the cardiotoxic mechanisms of Doxorubicin, Aclarubicin, and Amrubicin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: